Application 103705

Type
BLA
Sponsor
GENENTECH

Application Products#

Product, Drug, Ingredient table
ProductDrugIngredientFormStrengthReference drugReference standard
001RITUXANRITUXIMABSOLUTION;INTRAVENOUS100MG/10ML (10MG/ML)NoNo
002RITUXANRITUXIMABSOLUTION;INTRAVENOUS500MG/50ML (10MG/ML)NoNo

NDC Listings For This Application#

NDC, Name, Nonproprietary name table
NDCNameNonproprietary nameLabelerMarketing categoryStatus
50242-051RituxanrituximabGenentech, Inc.BLACurrent
50242-051RituxanrituximabGenentech, Inc.BLACurrent
50242-051RituxanrituximabGenentech, Inc.BLACurrent
50242-051RituxanrituximabGenentech, Inc.BLACurrent
50242-051RituxanrituximabGenentech, Inc.BLACurrent
50242-051RituxanrituximabGenentech, Inc.BLACurrent
50242-051RituxanrituximabGenentech, Inc.BLACurrent
50242-051RituxanrituximabGenentech, Inc.BLACurrent
50242-051RituxanrituximabGenentech, Inc.BLACurrent
50242-051RituxanrituximabGenentech, Inc.BLACurrent
50242-051RituxanrituximabGenentech, Inc.BLACurrent
50242-053RituxanrituximabGenentech, Inc.BLACurrent
50242-053RituxanrituximabGenentech, Inc.BLACurrent
50242-053RituxanrituximabGenentech, Inc.BLACurrent
50242-053RituxanrituximabGenentech, Inc.BLACurrent
50242-053RituxanrituximabGenentech, Inc.BLACurrent
50242-053RituxanrituximabGenentech, Inc.BLACurrent
50242-053RituxanrituximabGenentech, Inc.BLACurrent
50242-053RituxanrituximabGenentech, Inc.BLACurrent
50242-053RituxanrituximabGenentech, Inc.BLACurrent
50242-053RituxanrituximabGenentech, Inc.BLACurrent
50242-053RituxanrituximabGenentech, Inc.BLACurrent

Documents#

Document, Submission type, Date table
DocumentSubmission typeDate
69713SUPPL2021-12-21
69634SUPPL2021-12-19
69478SUPPL2021-12-06
69456SUPPL2021-12-03
69455SUPPL2021-12-03
68004SUPPL2021-07-01
67998SUPPL2021-07-01
67997SUPPL2021-07-01
64505SUPPL2020-09-04
64458SUPPL2020-09-01
62156SUPPL2020-03-17
62155SUPPL2020-03-17
61640SUPPL2020-01-24
61632SUPPL2020-01-24
61510SUPPL2020-01-10
61119SUPPL2019-12-03
60180SUPPL2019-10-01
60179SUPPL2019-10-01
60167SUPPL2019-10-01
57532SUPPL2019-02-13
57357SUPPL2019-01-28
56076SUPPL2018-10-23
56042SUPPL2018-10-19
54562SUPPL2018-06-14
54536SUPPL2018-06-12
53615SUPPL2018-04-05
53607SUPPL2018-04-04
31623SUPPL2014-08-14
39680SUPPL2014-08-13
43276SUPPL2014-08-01
18619SUPPL2013-09-27
9424SUPPL2013-09-26
18618SUPPL2013-05-14
9423SUPPL2013-05-13
9422SUPPL2012-10-22
9420SUPPL2012-10-22
39679SUPPL2012-10-19
39677SUPPL2012-10-19
39678SUPPL2012-07-30
9421SUPPL2012-07-17
18617SUPPL2012-04-24
31622SUPPL2012-04-19
31621SUPPL2012-02-23
39676SUPPL2012-02-22
9419SUPPL2011-04-22
18616SUPPL2011-04-21
9418SUPPL2011-02-04
18614SUPPL2011-01-31
31620SUPPL2011-01-14
18615SUPPL2011-01-10
31619SUPPL2010-02-25
31618SUPPL2010-02-25
18613SUPPL2010-02-19
18612SUPPL2010-02-19
31617SUPPL2009-10-26
18611SUPPL2009-10-22
31616SUPPL2008-09-16
9417SUPPL2008-09-16
39675SUPPL2008-01-31
39674SUPPL2008-01-30
9414SUPPL2008-01-30
18610SUPPL2007-10-10
9416SUPPL2007-10-04
18609SUPPL2007-08-30
9415SUPPL2007-08-30
18608SUPPL2007-03-07
31615SUPPL2007-03-06
9413SUPPL2006-10-05
39673SUPPL2006-10-02
18607SUPPL2006-10-02
18606SUPPL2006-03-14
9412SUPPL2006-03-14
18605SUPPL2006-02-14
43275ORIG2004-09-22
39672ORIG2004-09-22
31614ORIG2004-09-22
23942ORIG2004-09-22